Karyopharm Therapeutics (KPTI) Competitors $5.93 -0.10 (-1.66%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.98 +0.04 (+0.76%) As of 10/17/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. CRBP, FBRX, DERM, FATE, PLX, IPHA, TNXP, FTLF, AVTX, and BHSTShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), Tonix Pharmaceuticals (TNXP), FitLife Brands (FTLF), Avalo Therapeutics (AVTX), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Corbus Pharmaceuticals Forte Biosciences Journey Medical Fate Therapeutics Protalix BioTherapeutics Innate Pharma Tonix Pharmaceuticals FitLife Brands Avalo Therapeutics BioHarvest Sciences Karyopharm Therapeutics (NASDAQ:KPTI) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Which has more risk and volatility, KPTI or CRBP? Karyopharm Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500. Do analysts prefer KPTI or CRBP? Karyopharm Therapeutics currently has a consensus target price of $18.20, indicating a potential upside of 206.91%. Corbus Pharmaceuticals has a consensus target price of $45.43, indicating a potential upside of 135.14%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Corbus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Corbus Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has preferable earnings & valuation, KPTI or CRBP? Corbus Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.35-$76.42M-$14.59-0.41Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-4.06 Does the media refer more to KPTI or CRBP? In the previous week, Karyopharm Therapeutics had 9 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 14 mentions for Karyopharm Therapeutics and 5 mentions for Corbus Pharmaceuticals. Karyopharm Therapeutics' average media sentiment score of 0.73 beat Corbus Pharmaceuticals' score of 0.72 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KPTI or CRBP more profitable? Corbus Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% Corbus Pharmaceuticals N/A -43.65%-39.62% Do institutionals & insiders hold more shares of KPTI or CRBP? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 2.8% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCorbus Pharmaceuticals beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.41M$2.62B$6.13B$10.55BDividend YieldN/A57.79%5.72%4.83%P/E Ratio-0.4123.3185.7827.06Price / Sales0.35778.09612.92132.30Price / CashN/A27.2425.8230.35Price / Book-0.275.3212.226.58Net Income-$76.42M$33.06M$3.33B$276.84M7 Day Performance5.52%-0.91%0.67%-0.72%1 Month Performance9.61%7.35%6.88%2.16%1 Year Performance-54.56%-5.13%58.88%34.63% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics4.2959 of 5 stars$5.93-1.7%$18.20+206.9%-54.6%$51.41M$145.24M-0.41380CRBPCorbus Pharmaceuticals4.1299 of 5 stars$16.32+5.0%$45.43+178.4%+4.9%$190.45MN/A-3.4340News CoverageFBRXForte Biosciences2.7832 of 5 stars$14.75-3.4%$68.00+361.0%+155.4%$189.85MN/A-0.915News CoverageAnalyst DowngradeOptions VolumeDERMJourney Medical2.0001 of 5 stars$7.00-2.9%$12.17+73.8%+17.6%$189.69M$56.13M-18.4290FATEFate Therapeutics4.1576 of 5 stars$1.39-15.0%$3.30+137.4%-54.5%$188.56M$13.63M-0.96550PLXProtalix BioTherapeutics2.1087 of 5 stars$2.45+3.8%$15.00+512.2%+70.6%$188.17M$61.95M-18.85200Gap DownIPHAInnate Pharma2.0843 of 5 stars$1.93-4.9%$6.50+236.8%+6.4%$187.13M$21.77M0.00220Gap UpTNXPTonix Pharmaceuticals2.7851 of 5 stars$20.06-5.3%$70.00+249.0%+3.4%$185.75M$10.09M-0.5150Short Interest ↑FTLFFitLife Brands3.5511 of 5 stars$20.15+2.3%$23.00+14.1%+13.2%$185M$64.47M23.9920AVTXAvalo Therapeutics2.9471 of 5 stars$13.67-2.0%$31.67+131.7%+37.3%$183.48M$440K0.0040News CoveragePositive NewsAnalyst ForecastShort Interest ↑BHSTBioHarvest Sciences2.124 of 5 stars$12.50+13.2%$13.67+9.3%N/A$181.33M$25.19M-17.86N/AAnalyst UpgradeShort Interest ↑ Related Companies and Tools Related Companies Corbus Pharmaceuticals Competitors Forte Biosciences Competitors Journey Medical Competitors Fate Therapeutics Competitors Protalix BioTherapeutics Competitors Innate Pharma Competitors Tonix Pharmaceuticals Competitors FitLife Brands Competitors Avalo Therapeutics Competitors BioHarvest Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
